TIDES Expert Opinion Webinar Series
Nucleic Acid–based Therapies: Challenges and Opportunities during Nonclinical Development
LEARN FROM THE BRIGHTEST MINDS IN THE OLIGONUCLEOTIDE, PEPTIDE & MRNA THERAPEUTICS INDUSTRY
Each year, TIDES' scientific agenda includes 150+ of the industry's top scientists to present the latest science and industry updates across the entire spectrum from discovery, preclinical, clinical development through CMC, Manufacturing and commercialization of therapeutics and vaccines for oligos, peptides, mRNA and genome editing products.
ACCESS NOVEL SCIENCE ACROSS THE ENTIRE OLIGONUCLEOTIDE, PEPTIDE, AND MRNA SPECTRUM
Cross-fertilize Ideas and Best Practices with Industry Experts Across Multiple Discipline Areas.
The TIDES USA program features 4 concurrent tracks covering the following 6 scientific themes including in-depth development strategies, trends, and technologies across the entire spectrum of oligonucleotides, peptides, mRNA, and genome editing. Your registration provides access to the presentations across all 4 tracks, allowing you to create your own customized agenda.
Oligonucleotide Chemistry, Manufacturing & Controls
Comprehensive CMC, analytical, manufacturing and regulatory strategies for both drug substance and drug product to accelerate oligonucleotide product development.
Oligonucleotide Discovery, Preclinical and Clinical
Design oligonucleotides with better drug-like properties to accelerate your products to the clinic and to market. The latest preclinical and clinical updates to benchmark your research and improve your clinical efforts.
Peptide Chemistry, Manufacturing & Controls
Improve process efficiencies and overcome challenges in process development, CMC and manufacturing. Understand regulatory expectations, new technologies and alternative approaches for emerging complex molecules.
Peptide Discovery, Preclinical and Clinical
Explore new frontiers in peptide synthesis, discovery, design and engineering to improve targeting, delivery and drug-like properties. Case studies on the latest preclinical and clinical successes of peptides and peptide-like scaffolds and structures.
mRNA Therapeutics/Vaccines & Genome Editing
Hear updates on discovery strategies, clinical progress and CMC approaches for mRNA therapeutics and vaccines from industry-leading companies, and learn about state-of-the-art technologies for genome editing applications and hear about progress in genome editing delivery
Drug Delivery Innovations
Explore new technologies and approaches in the delivery of macromolecular therapeutics featuring multiple case studies of the delivery of oligonucleotides, peptides, mRNA therapeutics and genome editing delivery strategies. Learn about cutting-edge delivery advances including targeted delivery approaches for oligonucleotides, device-based delivery strategies and oral delivery of peptides.
Get the latest event updates
CONNECT WITH THE INDUSTRY ANYWHERE IN THE WORLD
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals. Our 2021 hybrid event will offer you the most flexibility needed during these uncertain times.
For more information, click the link below or email Mike Dunnet directly at email@example.com.
Looking for Additional Training Opportunities?
Join us at one of our upcoming virtual TIDES training courses.
Informa training courses provide in-depth teaching and discussion about highly technical and scientific topics relevant to the TIDES community that can not be covered at a conference. With 6+ hours of dedicated instruction in a classroom-like (teacher/student) environment, a training course will offer you interactive opportunities with the instructor and fellow attendees so you can get your most pressing questions answered in a much more individualized setting.
Introduction to Oligonucleotide Conjugate Strategies
October 26-28 (Virtual)
Understand how to best design oligonucleotide conjugates — from simple starting building blocks to the full oligonucleotide conjugate. With full consideration of the biological behavior of both the finished molecule and all of its individual components.